top of page
MyNauseaRisk™ Test used to Predict CINV Chemotherapy Induced Nausea Vomiting
Delayed Chemotherapy-Induced Nausea and Vomiting is experienced by up to 40% of cancer patients who receive emetogenic chemotherapy as a standard of care, especially for common colon, lung, breast, ovarian, and head and neck cancers.
Nausea is the side effect most feared by cancer patients, but it is a subjective symptom with no objective measurement to predict or monitor. No real-time methods have been made available to monitor the core metabolic system that influences the occurrence of delayed CINV in individual patients.
Delayed CINV cases increase emergency room visits and strongly influence a patient’s overall health and social life, negatively impacting family, work and treatment adherence. While use of anti-emetic drugs has improved care, delayed CINV still affects many who receive emetogenic chemotherapy.
Our technology detects a naturally occurring variation among individuals in the glutathione recycling efficiency in red blood cells, which the LIMR team discovered is correlated with the incidence of patient-reported delayed CINV and CPIN.
MyNauseaRisk™
The MyNauseaRisk™ test monitors a cancer patient’s core metabolic system and can identify those who are at high risk for delayed CINV. This test is predictive before chemotherapy is administered, enabling appropriate prophylactic care beforehand.
About
About MYNARI Biomedical
MYNARI Biomedical is a science-driven diagnostic company located in the Philadelphia region. Our purpose is to commercialize novel medical discoveries and deliver life-changing innovations. MYNARI has licensed the exclusive rights to the patented and patent pending MyNauseaRisk™ diagnostic test, and is currently developing the test for commercial use.
bottom of page